Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A

Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A

SSZSE:301126
8.38
CNY
-0.25
(-2.90%)
-1.09EPS
2.16BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
15.53
32.31
90.89
20.38
15.43
14.59
15.97
15.15
16.71
16.11
19.35
25.6
25.04
24.79
Basic EPS, GAAP
0.28
0.43
2.76
0.62
0.61
0.52
0.57
0.42
0.44
0.25
0.17
0.13
-1.18
-1.17
Free Cash Flow per Basic Share
0.34
-1.6
-4.37
-1.53
-0.96
-0.25
0.67
-1.28
-1.26
-3.44
-0.99
-0.8
-1.23
- -
Dividend per Share
0.09
0.17
0.88
0.18
0.18
0.19
0.24
0.2
0.2
0.2
0.36
0.45
0.55
0.26
Book Value per Share
0.12
0.81
2.05
2.5
5.96
5.69
6.31
6.72
8.13
8.34
8.46
8.55
7.24
7.29
Tangible Book Value per Share
0.12
0.81
2.05
2.5
5.74
5.51
6.14
6.55
8.01
6.99
4.32
2.45
1.4
1.33
Basic Weighted Avg Shares
10
49
17
93
131
150
154
154
155
204
202
204
205
204
Sales/Revenue/Turnover
154
1,588
1,537
1,899
2,022
2,189
2,457
2,340
2,592
3,292
3,904
5,233
5,144
5,052
Operating Margin (%)
2.96
2.86
5.24
5.35
7.09
6.8
6.63
5.49
5.63
4.06
3.7
4
2.13
2.23
Depreciation Expense
- -
1
- -
1
8
9
9
13
23
42
83
147
156
- -
Net Income, GAAP
3
21
47
58
80
78
88
65
68
51
34
27
-242
-238
Effective Tax Rate (%)
25.95
31.71
25.39
26.22
27.31
28.33
26.35
28.04
28.9
27.37
21.72
32.46
- -
- -
Profit Margin (%)
1.8
1.33
3.04
3.04
3.95
3.56
3.57
2.77
2.63
1.55
0.88
0.51
-4.71
-4.71
Working Capital
15
100
255
337
542
795
841
855
1,482
1,197
760
407
-25
55
LT Debt
- -
- -
- -
- -
- -
156
122
116
150
299
939
1,019
722
691
Total Equity
16
102
258
316
751
864
977
1,041
1,679
1,817
1,782
1,849
1,593
1,629
Return on Invested Capital (%)
11.62
15.65
13
9.49
8.4
6.74
6.96
4.31
3.27
1.91
1.03
1.12
- -
- -
Return on Capital (%)
15.1
14.3
16.99
12.17
15.23
16.48
17.61
8.37
4.39
2.53
2.06
1.44
- -
- -
Return on Common Equity (%)
25.92
35.86
25.92
20.15
14.99
9.66
9.52
6.43
5.02
3
1.98
1.52
-14.95
-14.61

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,935
2,734
2,710
LT Borrowings
614
719
581
LT Finance Leases
116
120
110
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
205
205
205
Market Capitalization
2,313
1,756
2,161

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,078
4,022
3,889
Cash, Cash Equivalents & STI
530
590
303
Accounts Receivable, Net
2,019
1,902
1,878
Inventories
923
900
927
Total Current Liabilities
4,032
3,845
3,833
Payables & Accruals
- -
- -
- -
ST Debt
2,935
2,734
2,710
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.26%
11.49%
-13.83%
Free Cash Flow
-43.24%
44.94%
55.58%
Net Income, GAAP
-104.15%
-217.53%
-1,012.36%
Sales/Revenue/Turnover
13.45%
17.75%
-1.7%
Total Cash Common Dividend
24.58%
31.52%
21.27%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,280
1,320
1,383
1,250
5,233
2025
1,300
1,409
- -
1,014
5,144
2026
1,384
1,317
1,336
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.06
0.02
-0.05
0.13
2025
0.02
-0.01
- -
-1.21
-1.18
2026
0.03
0.01
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.11
0.1
0.16
0.45
2025
0.12
0.28
- -
-0.05
0.55
2026
0.09
0.12
0.1
- -
- -

Company Description

CEO
Sheng Li Hu
Full Time Employees
5,339
Sector
Distribution services
Industry
Medical distributors
Address
Changsha China
IPO Date
Dec 7, 2021
Business
Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. is a China-based integrated healthcare and pharmaceutical enterprise engaged in pharmaceutical distribution, specialized retail pharmacy operations, pharmaceutical research and manufacturing, and medical healthcare services. Founded in 2002 and headquartered in Changsha, Hunan Province, the company operates across the healthcare value chain through four principal business divisions: Pharmaceutical Distribution, Pharmaceutical Retail, Pharmaceutical Manufacturing, and Medical Services. In its Pharmaceutical Distribution division, the company engages in the wholesale, logistics, and supply chain distribution of prescription medications, over-the-counter drugs, biopharmaceuticals, traditional Chinese medicines, medical devices, diagnostic reagents, and consumables to public hospitals, grassroots healthcare centers, and medical institutions primarily throughout Hunan Province. In its Pharmaceutical Retail division, the company manages an extensive network of retail pharmacies, specialized Direct-to-Patient pharmacies, and designated chronic disease pharmacies, providing high-value specialty pharmaceuticals for oncology, immunology, and rare diseases, alongside prescription filling, health consultation, disease management, and online-to-offline retail pharmaceutical services. In its Pharmaceutical Manufacturing division, through operating subsidiaries including Dajia Weikang Biopharmaceutical Co., Ltd. and Hunan Tianji Caotang Pharmaceutical Co., Ltd., the company develops, produces, and commercializes chemical pharmaceuticals, traditional Chinese medicines, and health formulations; core manufactured products include Xiaojianzhong granules; Jiuwei Gantai capsules; Azithromycin granules; Qingre Sanjie capsules; Naodesheng pills; and various dosage forms across cardiovascular, digestive, anti-infective, and respiratory therapeutic categories, supplemented by medical devices, dietary supplements, cosmetics, and disinfectant products. In its Medical Services division, the company operates specialized medical institutions, including the Changsha Jiachen Reproductive and Genetics Hospital, offering assisted reproductive technologies, genetic diagnosis, chronic disease rehabilitation, and specialized clinical care. In recent developments, Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. has expanded its geographic footprint beyond Hunan Province through a series of retail pharmacy chain acquisitions across China, securing controlling interests in regional chains including Ningxia Delixin Pharmacy Co., Ltd., Yinchuan Meihetai Pharmaceutical Chain Co., Ltd., Shanxi Simaile Pharmacy Chain Co., Ltd., and Anhui Dajiaweikang Health Pharmacy Co., Ltd., while integrating traditional Chinese medicine manufacturing through the acquisition of Hunan Tianji Caotang Pharmaceutical Co., Ltd. Additionally, the company established a specialized Silver Economy Business Division to expand integrated medical and elder care solutions, accelerated research and development in regenerative medicine and cell therapy through dedicated research institutes, implemented centralized supply chain and digital transformation initiatives across acquired retail networks, and executed corporate share repurchase programs to support long-term capital management.